Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Inovio’s Zika Vaccine Is Approved for Clinical Trials

By Stephanie Guzowski | June 20, 2016

Zika virus

The U.S. Food and Drug Administration on Monday for the first time granted clinical trial approval for an experimental Zika vaccine.

The vaccine, called GLS-5700, is manufactured by Inovio Pharmaceuticals of Plymouth Meeting, Pa. and GeneOne Life Science, of Seoul, South Korea. Earlier today, the companies announced they will begin within the next few weeks a Phase 1 trial with 40 healthy subjects to evaluate the safety, tolerability and immune response generated by the vaccine.

“We are proud to have attained the approval to initiate the first Zika vaccine study in human volunteers,” Inovio’s president and CEO, Dr. J. Joseph Kim, said in a prepared statement.

Interim trial results are expected later this year. Preclinical results have been promising: The vaccine “induced robust antibody and T cell responses in small and large animal models.”

The mosquito-driven Zika virus is associated with severe birth defects, like microcephaly, which is characterized by a significantly small head and brain developmental problems. The Centers for Disease Control and Prevention (CDC) announced last Friday that Puerto Rico is part of the Zika epidemic. The U.S. territory has more than 1,700 cases, including 191 in pregnant women.

Last week, the CDC reported three babies with Zika-linked birth defects were born in the U.S.

French drugmaker Sanofi is testing potential Zika vaccines on animals, and said it plans to begin clinical trials next year.

Still, these are the beginning stages of a Zika vaccine; it could be years of late-stage trial design and analysis before a vaccine reaches approval status.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50